Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Diabetes, Obesity & Metabolism|September 2, 2022
Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trialRory J McCrimmon, Philip Home, Alice Cheng, et al.
Diabetes Care|July 23, 2020
Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized TrialJulio Rosenstock, Antonio Nino, Joseph Soffer, et al.
Diabetes Care|May 1, 2013
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)Matthew C Riddle, Ronnie Aronson, Philip Home, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 7, 2013
Comparison of National/Regional Diabetes Guidelines for the Management of Blood Glucose Control in non-Western CountriesPhilip Home, Jihad Haddad, Zafar Ahmed Latif, et al.
Diabetes, Obesity & Metabolism|July 24, 2020
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysisPhilip Home, Lawrence Blonde, Sanjay Kalra, et al.
Clinical Therapeutics|April 18, 2017
Incorporating Site-less Clinical Trials Into Drug Development: A Framework for ActionIrl B Hirsch, Joe Martinez, E Ray Dorsey, et al.
Diabetes, Obesity & Metabolism|April 3, 2025
Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta-analysis of non-Asian studiesPhilip Home, Felipe Lauand, Khier Djaballah, et al.
Diabetes Care|April 28, 2004
Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trialPhilip Home, Paul Bartley, David Russell-Jones, et al.
Diabetes Care|May 24, 2014
Insulin therapy in people with type 2 diabetes: opportunities and challenges?Philip Home, Matthew Riddle, William T Cefalu, et al.
Diabetes Research and Clinical Practice|October 29, 2017
A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetesPhilip Home, R Ravi Shankar, Ira Gantz, et al.
Pageof 5